LBF20207PG48: Difference between revisions
No edit summary |
No edit summary |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
|LipidBank=XPR1796 | |LipidBank=XPR1796 | ||
|LipidMaps=- | |LipidMaps=- | ||
|SysName=9beta,11alpha,15S- | |SysName=(9beta,11alpha,15S) -Trihydroxy- (8beta) -prosta- (cis-5,trans-13) -dien-1-oic acid | ||
|Common Name=&&8-iso Prostaglandin | |Common Name=&&8-iso Prostaglandin F_2 beta&&(9beta,11alpha,15S) -Trihydroxy- (8beta) -prosta- (5Z,13E) -dien-1-oic acid&& | ||
|Source= | |Source= | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=8-iso PGF2 | |Biological Activity=8-iso PGF2 beta has been reported to show very weak contraction of human umbilical vein artery and does not promote aggregation of human whole blood.[[Reference:Oliveira_L:Stallwood_NA:Crankshaw_DJ:,Br. J. Pharmacol.,2000,129,509|{{RelationTable/GetFirstAuthor|Reference:Oliveira_L:Stallwood_NA:Crankshaw_DJ:,Br. J. Pharmacol.,2000,129,509}}]][[Reference:Cranshaw_JH:Evans_TW:Mitchell_JA:,Br. J. Pharmacol.,2001,132,1699|{{RelationTable/GetFirstAuthor|Reference:Cranshaw_JH:Evans_TW:Mitchell_JA:,Br. J. Pharmacol.,2001,132,1699}}]] | ||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Latest revision as of 08:37, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1796 |
| LipidMaps | - |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20207PG48 |
| 8-iso Prostaglandin F2β | |
|---|---|
| |
| Structural Information | |
| (9β,11α,15S) -Trihydroxy- (8β) -prosta- (cis-5,trans-13) -dien-1-oic acid | |
| |
| Formula | C20H34O5 |
| Exact Mass | 354.240624198 |
| Average Mass | 354.48096000000004 |
| SMILES | C(CC[C@H](O)C=C[C@H]([C@@H]1CC=CCCCC(O)=O)[C@@H](C[C@H]1O)O)CC |
| Physicochemical Information | |
| 8-iso PGF2 beta has been reported to show very weak contraction of human umbilical vein artery and does not promote aggregation of human whole blood. Oliveira_L et al. Cranshaw_JH et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
